Goldline Pharmaceutical's IPO allotment is set to be finalized today, May 15, 2026, with the basis of allotment expected to be announced by late evening. Investors can check their allotment status online through BSE's IPO allotment status page or Bigshare Services using their PAN details or application number. The ₹11.61 crore IPO was subscribed 781.85 times, with bids for 1,53,86,88,000 shares against the offer size of 19,68,000 shares. The allotment will be finalized by May 15, with shares scheduled to list on BSE SME on May 19 at 10 AM.
Investors demonstrated robust interest across all categories, with 153.86 crore equity shares bid against the offer size of 19.68 lakh shares via 1.66 lakh applications. As reported by BSE, the non-institutional investors led the subscription with 1,227.90 times their allotted quota, while the retail investor portion was subscribed 881.15 times and qualified institutional buyers subscribed 180.22 times. The IPO was purely a fresh issuance of 27 lakh shares with no offer for sale component, with each lot consisting of 3,000 shares and minimum investment of 6,000 shares for individual investors. Within the NII category, high-value bids above ₹10 lakh saw particularly aggressive participation, subscribed over 2,011.14 times.
According to investorgain.com, Goldline IPO shares are trading at ₹58 in the grey market, reflecting a grey market premium of 34.88% compared to the upper price band of ₹43. The company plans to utilize ₹8.35 crore of IPO proceeds for repayment of certain outstanding borrowings, with the remaining amount allocated for general corporate purposes. As reported by BSE, total borrowings in the company's books amounted to ₹9.1 crore as of March 2026. The grey market premium had reached as high as ₹25 when the issue opened for Day 3 subscription, indicating a possible listing gain of more than 55%.
Goldline Pharmaceutical operates as a marketing company for pharmaceutical products under the brand Goldline, without manufacturing any pharma products. According to BSE, the company operates through a third-party manufacturing model through contractual arrangements with 15 manufacturers and 8 distributors. The firm conducts market research, specifications and demand analysis, which are then passed on to manufacturers who produce products based on Goldline's requirements. Cumulative Capital acted as the merchant banker for the Goldline Pharmaceutical IPO, facilitating this successful public offering in the SME segment. The company's portfolio is divided into five segments: Goldline Pharma (42 products), Goldline Cardinal (54 products), Goldline Aayushman (18 products), Goldline InLife (22 products), and Goldline Wellness (10 products), covering multiple therapeutic segments including orthopaedics, ENT, gastroenterology, neurology, urology, surgery, diabetes, cardiology, paediatrics, neonatology, critical care, and cancer treatment.
